Abstract
Background: Exhaled breath condensate (EBC) 8-isoprostane levels were found increased in chronic obstructive pulmonary disease. However, the relation between EBC 8-isoprostane and parameters which have a known predictive value in COPD, remains vastly unknown, and so does subsequently its clinical value. Objectives: To investigate the relationship between 8-isoprostane level in EBC and clinical parameters, radiological indices and airway inflammation in COPD patients. Materials and Methods: We studied 18 COPD patients (all ex-smokers) and 12 healthy controls (5 ex-smokers and 7 never-smokers). All patients underwent clinical evaluation, sputum induction, high-resolution computed tomography (HRCT) of the thorax and EBC 8-isoprostane measurement. 8-Isoprostane levels were correlated with markers that reflect disease severity, such as dyspnea severity, FEV1 (%pred), emphysema changes and bronchiectasis in HRCT. Emphysema was quantified as the percentage of lung area with attenuation values < –950 Hounsfield units. Results: 8-Isoprostane levels were significantly elevated in EBC of patients with COPD [mean (SE) 18.1 (2) vs. 5.6 (0.7) pg/ml, p = 0.0001], irrespective of lung function impairment. 8-Isoprostane levels were correlated with emphysema score in HRCT (r2 = 0.43, p = 0.001) as well as with Medical Research Council dyspnea scale score (rho = 0.61, p = 0.005). Conclusion: Our findings suggest that EBC 8-isoprostane levels may reflect the extension of lung emphysema in COPD patients. In this respect, further investigation is required in order to evaluate the possible role of EBC 8-isoprostane in assessing disease progress in COPD patients.
Journal Section:
Editor's choice
References
1.
Celli BR, MacNee W: ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–946.
2.
Dekhuijzen PNR, Aben KKH, Dekker I, Aarts LPHJ, Wielders PLML, van Heerwarden CLA, Bast A: Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154:813–816.
3.
Maestrelli P, El Messlemani AH, De Fina O, Nowicki Y, Saetta M, Mapp C, Fabbri LM: Increased expression of heme oxygenase (HO)-1 in alveolar spaces and HO-2 in alveolar walls of smokers. Am J Respir Crit Care Med 2001;15:1508–1513.
4.
Barnes PJ, Shapiro SD, Pauwels RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672–688.
5.
Rahman I, Gilmour PS, Jimenez LA, MacNee W: Oxidative stress and TNF-alpha induce histone acetylationand NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol Cell Biochem 2002;234–235:239–248.
6.
Gutteridge GM: Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995;41:1819–1828.
7.
Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, Barnes PJ: Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000;162:1175–1177.
8.
Kostikas K, Papatheodorou G, Psathakis K, Panagou P, Loukides S: Oxidative stress in expired breath condensate of patients with COPD. Chest 2003;124:1373–1380.
9.
Biernacki WA, Kharitonov SA, Barnes PJ: Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003;58:294–298.
10.
Kostikas K, Papatheodorou G, Ganas K, Psathakis K, Panagou P, Loukides S: pH in expired breath condensate of patients with inflammatory airway diseases. Am J Respir Crit Care Med 2002;15:165:1364–1370.
11.
Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jobsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G, Vogelberg C, Wirtz H; ATS/ERS Task Force on Exhaled Breath Condensate: Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005;26:523–548.
12.
Makris D, Tzanakis N, Moschandreas J, Siafakas NM: Dyspnea assessment and adverse events during sputum induction in COPD. BMC Pulm Med 2006;6:17.
13.
American Thoracic Society (ATS): ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–117.
14.
Martinez JA, Straccia L, Sobrani E, Silva GA, Vianna EO, Filho JT: Dyspnea scales in the assessment of illiterate patients with chronic obstructive pulmonary disease. Am J Med Sci 2000;320:240–243.
15.
American Thoracic Society: Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995;152:1107–1136.
16.
Tsiligianni J, Tzanakis N, Kyriakou D, Chrysofakis G, Siafakas N, Bouros D: Comparison of sputum induction with bronchoalveolar lavage cell differential counts in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:205–210.
17.
Gevenois PA, De Vuyst P, de Maertelaer V, Zanen J, Jacobovitz D, Cosio MG, Yernault JC: Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1996;154:187–192.
18.
Baldi S, Miniati M, Bellina CR, Battolla L, Catapano G, Begliomini E, Giustini D, Giuntini C: Relationship between extent of pulmonary emphysema by high-resolution computed tomography and lung elastic recoil inpatients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:585–589.
19.
Ooi GC, Khong PL, Chan-Yeung M, Ho JCM, Chan PKS, Lee JCK, Lam WK, Tsang KWT: High-resolution CT quantification of bronchiectasis: clinical and functional correlation. Radiology 2002;225:663–672.
20.
Psathakis K, Papatheodorou G, Plataki M, Panagou P, Loukides S, Siafakas NM, Bouros D: 8-Isoprostane, a marker of oxidative stress, is increased in the expired breath condensate of patients with pulmonary sarcoidosis. Chest 2004;125:1005–1011.
21.
Carpenter CT, Price PV, Christman BW: Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury or ARDS. Chest 1998;114:1653–1659.
22.
Montuschi P, Ciabattoni G, Paredi P, Pantelidis P, du Bois RM, Kharitonov SA, Barnes PJ: 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998;158:1524–1527.
23.
Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, Resta O, Gramiccioni E, Barnes PJ: Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax 2004;59:1016–1019.
24.
Tuder RM, Zhen L, Cho CY, Taraseviciene-Stewart L, Kasahara Y, Salvemini D, Voelkel NF, Flores SC: Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003;29:88–97.
25.
Wood LG, Garg ML, Simpson JL, Mori TA, Croft KD, Wark PA, Gibson PG: Induced sputum 8-isoprostane concentrations in inflammatory airway diseases. Am J Respir Crit Care Med 2005;171:426–430.
26.
Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, Reznek RH, Wedzicha JA: Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:400–407.
27.
Price DB, Tinkelman DG, Halbert RJ, Nordyke RJ, Isonaka S, Nonikov D, Juniper EF, Freeman D, Hausen T, Levy ML, Ostrem A, van der Molen T, van Schayck CP: Symptom-Based Questionnaire for Identifying COPD in Smokers. Respiration 2006;73:285–295.
28.
Barnes PJ: Future Advances in COPD Therapy. Respiration 2001;68:441–448.
29.
Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005–1012.
30.
Eltayara L, Becklake MR, Volta CA, Milic-Emili J: Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154:1726–1734.
31.
Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Lofdahl CG: Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005;25:98.
32.
Alexis NE, Hu SC, Zeman K: Induced sputum derives from the central airways: confirmation using a radiolabeled aerosol bolus delivery technique. Am J Respir Crit Care Med 2001;164:1964–1970.
33.
O’Donnell RA, Peebles C, Ward JA, Daraker A, Angco G, Broberg P, Pierrou S, Lund J, Holgate ST, Davies DE, Delany DJ, Wilson SJ, Djukanovic R: Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004;59:837–842.
34.
Antczak A, Kharitonov SA, Montuschi P, Gorski P, Barnes PJ: Inflammatory response to sputum induction measured by exhaled markers. Respiration 2005;72:594–599.
© 2007 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2007
You do not currently have access to this content.
